Singapore, Oct. 16 -- The Health Sciences Authority received information related to the study titled 'An open-label, roll-over study evaluating the long-term safety and efficacy of an oral dose of ver... Read More
Singapore, Oct. 16 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Open-Label, Randomized Study to Evaluate Inobrodib in Combination with Pom... Read More
Singapore, Oct. 16 -- The Health Sciences Authority received information related to the study titled 'A Long-Term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of... Read More
Singapore, Oct. 16 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose-Escalation Study to ... Read More
Singapore, Oct. 16 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Open-Label, Pharmacokinetic Study of Lepodisiran Administered as a Single Subcutaneous ... Read More
Singapore, Oct. 16 -- The Health Sciences Authority received information related to the study titled 'A Phase 2 Platform Basket Study Evaluating Advanced Therapies in Subjects with Moderately to Sever... Read More
Singapore, Oct. 16 -- The Health Sciences Authority received information related to the study titled 'Evaluating the Year-Round Immunogenicity of Standard-Dose Versus High-Dose Seasonal Influenza Vacc... Read More
Singapore, Oct. 16 -- The Health Sciences Authority received information related to the study titled 'Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion... Read More
Singapore, Oct. 16 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination with Darolutami... Read More
Singapore, Oct. 16 -- The Health Sciences Authority received information related to the study titled 'Tucatinib continuation protocol: an open label study for participants from tucatinib clinical stud... Read More